6 completed, 5 recruiting, 1 active not recruiting, 1 withdrawn. 13 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 6, Recruiting 5, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Recruiting 5 |
Follow Recurrent Cancer: new trials by email Literature Review of Recurrent Cancer trials Research Report on Recurrent Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors RO7617991, Tocilizumab - Refractory Cancer, Recurrent Cancer | Phase 1 | Withdrawn | Genentech, Inc. | 2024-09-30 | 2024-09-03 | |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Paxalisib, Opdualag, Irinotecan (drug) - Childhood Cancer, Childhood Solid Tumor | Phase 1 / Phase 2 | Recruiting | Australian & New Zealand Children's Haematology/Oncology Group | 90 | 2024-07-10 | 2026-01-28 |
| Personalized Neoantigen Peptide Vaccines for Solid Tumors Personalized Neoantigen Peptide Vaccine - Solid Tumors, Advanced Cancer | Phase 1 / Phase 2 | Recruiting | Seqker Biosciences, Inc. | 10 | 2024-03-01 | 2026-07-24 |
| Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy SNK02 - Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer | Phase 1 | Completed | NKGen Biotech, Inc. | 6 | 2023-08-23 | 2024-11-20 |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy - Refractory Cancer, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Immatics Biotechnologies GmbH | 400 | 2023-08-09 | 2026-09-01 |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor IMA401 (Phase Ia), Pembrolizumab (Phase Ia), IMA 401 (Phase Ib) - Refractory Cancer, Recurrent Cancer | Phase 1 | Active not recruiting | Immatics Biotechnologies GmbH | 95 | 2022-05-19 | 2026-04-30 |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors CEA CAR-T cells - Colorectal Cancer, Esophageal Cancer | Phase 1 | Completed | Chongqing Precision Biotech Co., Ltd | 30 | 2021-09-10 | 2026-07-09 |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients XRD-0394, Palliative radiotherapy - Metastasis, Locally Advanced Solid Tumor | Phase 1 | Completed | XRad Therapeutics Inc | 12 | 2021-08-24 | 2024-01-11 |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL Ibrutinib, Pembrolizumab, Rituximab - Primary Central Nervous System Lymphoma, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 37 | 2020-08-01 | 2026-10-21 |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy SNK01, Avelumab, Pembrolizumab - Refractory Cancer, Metastatic Cancer | Phase 1 | Completed | NKGen Biotech, Inc. | 27 | 2019-07-15 | 2023-11-13 |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product - Refractory Cancer, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Immatics US, Inc. | 375 | 2019-05-14 | 2026-05-13 |
| TCR-engineered T Cells in Solid Tumors: IMA202-101 IMA202 Product, IMADetect® - Solid Tumor, Adult, Refractory Cancer | Phase 1 | Completed | Immatics US, Inc. | 16 | 2019-05-02 | 2025-02-04 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors IRX 2, Nivolumab - Metastatic Cancer, Recurrent Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2019-02-13 | 2023-04-14 |
Recurrence (13) · Neoplasms (10) · Neoplasm Metastasis (5) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Lymphoma (1) · Melanoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Disease Attributes (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Neoplastic Processes (5) · Neoplasms by Site (4) · Neoplasms by Histologic Type (3) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Head and Neck Neoplasms (2) · Neoplasms (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1)
pembrolizumab (3) · Nivolumab (2) · Antibodies, Monoclonal (1) · Drug Therapy (1) · IRX 2 (1) · Irinotecan (1) · Opdualag (1) · Pharmaceutical Preparations (1) · Rituximab (1) · Temozolomide (1) · avelumab (1) · ibrutinib (1) · tocilizumab (1)
Immatics Biotechnologies GmbH (2) · Immatics US, Inc. (2) · NKGen Biotech, Inc. (2) · Australian & New Zealand Children's Haematology/Oncology Group (1) · Chongqing Precision Biotech Co., Ltd (1) · Dana-Farber Cancer Institute (1) · Genentech, Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Seqker Biosciences, Inc. (1) · XRad Therapeutics Inc (1)
United States (7) · Germany (4) · Australia (1) · Canada (1) · China (1) · Netherlands (1) · Thailand (1)
Cedrik Britten, M.D. (1) · Cedrik Britten, MD (1) · Daniel Morgenstern, Dr (1) · David Ziegler, Prof (1) · Jingwang Bi, M.D (1) · Lakshmi Nayak, MD (1) · Paul Chang, MPH (1) · Rohit Jain, MD, MPH (1)
2023 (1)